Insider Selling: Inogen, Inc (INGN) Director Sells 14,000 Shares of Stock

Inogen, Inc (NASDAQ:INGN) Director Raymond Huggenberger sold 14,000 shares of the business’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $91.67, for a total value of $1,283,380.00. Following the completion of the transaction, the director now directly owns 7,808 shares in the company, valued at approximately $715,759.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Raymond Huggenberger also recently made the following trade(s):

  • On Friday, July 14th, Raymond Huggenberger sold 14,000 shares of Inogen stock. The stock was sold at an average price of $92.96, for a total value of $1,301,440.00.
  • On Thursday, June 15th, Raymond Huggenberger sold 15,300 shares of Inogen stock. The shares were sold at an average price of $90.88, for a total value of $1,390,464.00.

Inogen, Inc (INGN) opened at 93.96 on Friday. The company’s 50-day moving average price is $94.32 and its 200-day moving average price is $83.24. Inogen, Inc has a 52-week low of $50.24 and a 52-week high of $98.33. The company has a market cap of $1.95 billion, a price-to-earnings ratio of 81.56 and a beta of 1.01.

Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Thursday, August 3rd. The medical technology company reported $0.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.10. The business had revenue of $64.10 million for the quarter, compared to the consensus estimate of $59.99 million. Inogen had a return on equity of 12.45% and a net margin of 10.36%. The business’s quarterly revenue was up 17.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.25 earnings per share. Equities research analysts expect that Inogen, Inc will post $1.21 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this piece can be viewed at https://transcriptdaily.com/2017/08/19/insider-selling-inogen-inc-ingn-director-sells-14000-shares-of-stock.html.

A number of research analysts have recently commented on INGN shares. J P Morgan Chase & Co upped their price target on Inogen to $102.00 and gave the company an “overweight” rating in a research report on Monday, June 26th. Needham & Company LLC restated a “buy” rating and issued a $96.00 target price on shares of Inogen in a research note on Wednesday, May 10th. Zacks Investment Research lowered Inogen from a “hold” rating to a “sell” rating in a research note on Wednesday, May 10th. Stifel Nicolaus upped their target price on Inogen from $65.00 to $75.00 and gave the stock a “hold” rating in a research note on Wednesday, May 10th. Finally, BidaskClub lowered Inogen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Three equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $91.60.

Several institutional investors have recently modified their holdings of the company. Guggenheim Capital LLC acquired a new position in shares of Inogen during the fourth quarter worth about $211,000. Teachers Advisors LLC increased its position in shares of Inogen by 4.9% in the fourth quarter. Teachers Advisors LLC now owns 27,041 shares of the medical technology company’s stock worth $1,816,000 after buying an additional 1,263 shares during the last quarter. Bank of Montreal Can increased its position in shares of Inogen by 66.4% in the first quarter. Bank of Montreal Can now owns 68,085 shares of the medical technology company’s stock worth $5,280,000 after buying an additional 27,162 shares during the last quarter. Louisiana State Employees Retirement System increased its position in shares of Inogen by 3.1% in the first quarter. Louisiana State Employees Retirement System now owns 6,600 shares of the medical technology company’s stock worth $512,000 after buying an additional 200 shares during the last quarter. Finally, State of Alaska Department of Revenue increased its position in shares of Inogen by 4.1% in the first quarter. State of Alaska Department of Revenue now owns 1,790 shares of the medical technology company’s stock worth $138,000 after buying an additional 70 shares during the last quarter.

About Inogen

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Insider Buying and Selling by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply